OBJECTIVE: Recently, a symptom index for identification of ovarian cancer, based on specific symptoms along with their frequency and duration, was proposed. The current study aimed at validation of this index in Korean population. METHODS: A case-control study of 116 women with epithelial ovarian cancer and 209 control women was conducted using questionnaires on eight symptoms. These included pelvic/abdominal pain, urinary urgency/frequency, increased abdominal size/bloating, difficulty eating/feeling full. The symptom index was considered positive if any of the 8 symptoms present for <1 year that occurred >12 times per month. The symptoms were compared between ovarian cancer group and control group using chi-square test. Logistic regression analysis was used to determine whether the index predicted cancer. Sensitivity and specificity of the symptom index were also determined. RESULTS: The symptom index was positive in 65.5% of women with ovarian cancer, in 31.1% of women with benign cysts, and in 6.7% of women on routine screening (ps<0.001). Significantly higher proportion of ovarian cancer patients were positive for each symptom as compared with control group (ps<0.001). Results from the logistic regression indicated that the symptom index independently predicted cancer (p<0.001; OR, 10.51; 95% CI, 6.14 to 17.98). Overall, the sensitivity and specificity of the symptom index were 65.5% and 84.7%, respectively. Analyses of sensitivity by stage showed that the index was positive in 44.8% of patients with stage I/II disease and in 72.9% of patients with stage III/IV disease. CONCLUSION: The current study supported previous studies suggesting that specific symptoms were useful in identifying women with ovarian cancer.
OBJECTIVE: Recently, a symptom index for identification of ovarian cancer, based on specific symptoms along with their frequency and duration, was proposed. The current study aimed at validation of this index in Korean population. METHODS: A case-control study of 116 women with epithelial ovarian cancer and 209 control women was conducted using questionnaires on eight symptoms. These included pelvic/abdominal pain, urinary urgency/frequency, increased abdominal size/bloating, difficulty eating/feeling full. The symptom index was considered positive if any of the 8 symptoms present for <1 year that occurred >12 times per month. The symptoms were compared between ovarian cancer group and control group using chi-square test. Logistic regression analysis was used to determine whether the index predicted cancer. Sensitivity and specificity of the symptom index were also determined. RESULTS: The symptom index was positive in 65.5% of women with ovarian cancer, in 31.1% of women with benign cysts, and in 6.7% of women on routine screening (ps<0.001). Significantly higher proportion of ovarian cancerpatients were positive for each symptom as compared with control group (ps<0.001). Results from the logistic regression indicated that the symptom index independently predicted cancer (p<0.001; OR, 10.51; 95% CI, 6.14 to 17.98). Overall, the sensitivity and specificity of the symptom index were 65.5% and 84.7%, respectively. Analyses of sensitivity by stage showed that the index was positive in 44.8% of patients with stage I/II disease and in 72.9% of patients with stage III/IV disease. CONCLUSION: The current study supported previous studies suggesting that specific symptoms were useful in identifying women with ovarian cancer.
Entities:
Keywords:
Case-control study; Early diagnosis; Ovarian cancer; Symptoms
Authors: I J Jacobs; S J Skates; N MacDonald; U Menon; A N Rosenthal; A P Davies; R Woolas; A R Jeyarajah; K Sibley; D G Lowe; D H Oram Journal: Lancet Date: 1999-04-10 Impact factor: 79.321
Authors: Isam Lataifeh; Donald E Marsden; Greg Robertson; Val Gebski; Neville F Hacker Journal: Aust N Z J Obstet Gynaecol Date: 2005-06 Impact factor: 2.100
Authors: Barbara A Goff; Lynn S Mandel; Charles W Drescher; Nicole Urban; Shirley Gough; Kristi M Schurman; Joshua Patras; Barry S Mahony; M Robyn Andersen Journal: Cancer Date: 2007-01-15 Impact factor: 6.860
Authors: M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Dresher; Pamela Paley; Nicole Urban Journal: Cancer Date: 2008-08-01 Impact factor: 6.860
Authors: Penelope M Webb; David M Purdie; Sonia Grover; Susan Jordan; Marie-Louise Dick; Adèle C Green Journal: Gynecol Oncol Date: 2004-01 Impact factor: 5.482
Authors: Barbara A Goff; Kimberly A Lowe; Jeannette C Kane; Marissa D Robertson; Marcia A Gaul; M Robyn Andersen Journal: Gynecol Oncol Date: 2011-11-06 Impact factor: 5.482
Authors: Kimberly A Lowe; M Robyn Andersen; Jeannette C Kane; Marissa D Robertson; Barbara A Goff Journal: J Nurse Pract Date: 2013-01 Impact factor: 0.767
Authors: Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer Journal: Health Technol Assess Date: 2020-11 Impact factor: 4.014
Authors: Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Weiguo He; Kristin Primm; Sharon H Giordano; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2022-07-04 Impact factor: 4.661
Authors: Garth Funston; Victoria Hardy; Gary Abel; Emma J Crosbie; Jon Emery; Willie Hamilton; Fiona M Walter Journal: Cancers (Basel) Date: 2020-12-08 Impact factor: 6.639
Authors: Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Kristin Primm; Sharon H Giordano; Larissa A Meyer Journal: Cancer Date: 2021-08-04 Impact factor: 6.860